Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Summary

This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2016-03-15

Primary completion

2017-01-01

Completion

2018-06-26

Drugs

Indications